Sandoz acquires rights to Perjeta biosimilar
Swiss generics and biosimilars leader Sandoz (SIX: SDZ) today announced the signing of a global license agreement to commercialize a proposed biosimilar of oncology medicine pertuzumab.
The agreement with Taiwan-based (6589: TW) is milestone-based for a total consideration of up to $152 million, including an upfront payment and further potential incentives dependent upon market performance. The reference medicine market is worth an estimated $4.1 billion in global sales, and pertuzumab will join the deep Sandoz pipeline with the strategic objective to capitalize on a projected ~$300 billion biosimilar market opportunity over the next 10 years. EirGenix
The reference medicine Perjeta, from Roche (ROG: SIX) is a humanized IgG1 monoclonal antibody that is used in combination with other therapies, including trastuzumab, to treat HER2-positive early breast cancer and HER2-positive metastatic or locally recurrent unresectable breast cancer. Roche posted Perjeta sales of 2.32 billion francs ($2.88 billion) for the first nine month of 2025, down 13% year-on-year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze